Abstract: The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16-HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.

Abstract: A method of treating scoliosis by adminstering .beta..sub.2 adrenergic agonists in amounts sufficient to correct the condition.

Abstract: The present invention pertains to the field of pain management in medicine. Methods for treating reflex sympathetic dystrophy (including causalgia) are provided, in which a haloalkylamine a adrenergic blocking agent and a local anesthetic are administered to the affected limb by intravenous regional block. Formulations which can be used in these methods are also provided. In a preferred embodiment, phenoxybenzamine and either lidocaine or procaine are administered to the affected limb using a Bier block procedure.

Abstract: The invention concerns murine antiidiotypic monoclonal antibodies which are the internal image of determinants recognized by a monoclonal antibody on high molecular weight-melanoma associated antigen (HMW-MAA), antibody derivatives, hybridoma cell lines secreting such antiidiotypic monoclonal antibodies, and processes for the preparation of such antiidiotypic monoclonal antibodies, of their derivatives and of the hybridoma cell lines. The murine antiidiotypic monoclonal antibodies are useful for the determination of antibodies directed against high molecular weight-melanoma associated antigen, for the modulation of the immune response to HMW-MAA and for the treatment of melanoma.

Abstract: A method for detecting halogenated precursors incorporated into DNA is presented. The method is based on the selective photolysis of DNA by ultraviolet (UV) light at the sites of an incorporated halogenated precursor, such as the thymidine base analogs 5-bromo-2-deoxyuridine (BrdUrd), 5-iodo-2-deoxyuridine (IdUrd), 5-fluoro-2-deoxyuridine (FdUrd), or 5-chloro-2-deoxyuridine (CldUrd). The 3'-hydroxyl termini of the DNA single strand breaks generated during photolysis may be marked directly or indirectly with a fluorescent label. The DNA termini are directly labeled with fluorochrome-conjugated deoxyuridine triphosphate (dUTP) catalyzed by exogenous terminal deoxynucleotidyl transferase or DNA polymerase (nick translation system). The DNA termini are indirectly labeled with either biotin- or digoxygenin-conjugated dUTP; the incorporated biotin or digoxygenin is then detected following binding of fluorochrome-conjugated avidin or anti-digoxygenin antibody, respectively.

Abstract: Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.

Abstract: The invention concerns murine antiidiotypic monoclonal antibodies which are the internal image of determinants recognized by a monoclonal antibody on high molecular weight-melanoma associated antigen (HMW-MAA), antibody derivatives, hybridoma cell lines secreting such antiidiotypic monoclonal antibodies, and processes for the preparation of such antiidiotypic monoclonal antibodies, of their derivatives and of the hybridoma cell lines. The murine antiidiotypic monoclonal antibodies are useful for the determination of antibodies directed against high molecular weight-melanoma associated antigen, for the modulation of the immune response to HMW-MAA and for the treatment of melanoma.

Abstract: An assay for determining patients either having Primary Open Angle Glaucoma or at risk of developing Primary Open Angle Glaucoma. The assay involves testing cells, preferably lymphocyte cells, for 3.alpha.-HSD activity and determining from the level of assayed activity whether the patient is either suffering from Primary Open Angle Glaucoma or at risk therefor.

Abstract: The invention relates to a method for treating the complications of diabetes mellitus which comprises the administration to an individual afflicted with diabetes mellitus of an effective amount of N-alpha acetyl arginine.

Abstract: Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.

Abstract: The present invention relates to a method of and composition for reducing intraocular pressure. The method comprises administering to a patient requiring such reduction of intraocular pressure a therapeutically effective amount of 12(R)-hydroxy-eicosa-5,8,10,14-tetraenoic acid (12(R)-HETE). The method of the present invention is particularly useful in treatment of all types of glaucoma. The method is also useful in lowering intraocular pressure in preparation for eye surgery, particularly for the removal of cataracts.

Abstract: Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.

Abstract: This invention relates to a method for determining the nucleotide sequence of DNA an RNA molecules. The method is automatable and avoids the use of radioactive labels and gel electrophoresis. The method is also adaptable for introducing site-specific mutations in DNA and RNA molecules.

Abstract: This invention relates to combinations and methods for the treatment of renal disease, cardiovascular disease and hypertension. More particularly, the invention relates to combinations of renal vasodilators and .alpha..sub.1 -adrenergic or ganglionic blocking agents. According to a preferred embodiment, atriopeptins having renal vasodilator activity are used in combination with .alpha..sub.1 -adrenergic blocking agents for treating renal disease, cardiovascular disease and hypertension. The blocking agent promotes sustained renal vasodilation, thereby enhancing renal blood flow and kidney function.

Abstract: An antigen, a water-soluble protein, is isolated from group A (beta-hemolytic) streptococci by suspending the streptococci in an aqueous medium and subjecting the resulting mixture to disintegration by various means whereby the streptococci cells are disrupted. The supernatant contains the antigen, which can be purified by fractionation, particularly chromatographic adsorption.